Polycythemia Vera · line 2 · Ruxolitinib (PV — HU-resistant / intolerant)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-RUX-PV |
| ID | IND-PV-2L-RUXOLITINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-PV |
| Sources | SRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025 SRC-RESPONSE-VANNUCCHI-2015 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L for HU-resistant/intolerant PV. Ukraine access constraint dominant (not reimbursed for PV).
Used By
Algorithms
ALGO-PV-2L- ALGO-PV-2L
Indication
IND-PV-ANAGRELIDE-CONTINUOUS- IND-PV-ANAGRELIDE-CONTINUOUS